HOME >> MEDICINE >> NEWS
NIAID awards $4 million to develop anti-radiation treatments

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has issued five awards totaling $4 million to fund the development of products that eliminate radioactive materials from the human body following radiological or nuclear exposure. The awards, which were granted under Project Bioshield authorities, complement NIAID's other medical countermeasure efforts to create safe and effective products of this type.

"These new grants will help identify new drug candidates that could be acquired by the strategic national stockpile of medical countermeasures, which is available to the public after a terrorist or nuclear attack or accidental radioactive exposure," says NIAID Director Anthony S. Fauci, M.D.

In the event of an attack by a nuclear explosive device or radiological "dirty bomb," individuals potentially could inhale, ingest or absorb through their skin radioactive atoms called radionuclides. Depending on the type of radionuclide that a person is exposed to, the particles may be excreted from the body or enter bones, organs or other tissues, which could have significant adverse health consequences. Through an initiative announced in 2005, NIAID already is working to speed the development of a series of products that can bind (chelate) internally with the radionuclides and eliminate (decorporate) them from the body. Radionuclide decorporation products currently are available in the strategic national stockpile, but NIAID is focusing on expanding the product pool, creating new treatments capable of eliminating a wider range of radionuclides, developing products that can eliminate radioactive material faster and in greater amounts; and developing products in formulations that could be distributed more easily in a mass casualty situation.

NIAID has awarded five grants totaling up to $4 million to fund work for a period of 18 months. The following principal investigators and univ
'"/>

Contact: Kathy Stover
kstover@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
25-Sep-2006


Page: 1 2

Related medicine news :

1. NIAID releases MDR/XDR Tuberculosis research agenda
2. NIAID DNA vaccine for H5N1 avian influenza enters human trial
3. NIAID media availability: Examining genetic variability of malaria parasite offers insight
4. Partnership between NIAID and Sequella yields promising new TB drug for clinical testing
5. NIAID announces leadership for newly restructured HIV/AIDS clinical trials networks
6. NIAID study finds higher dose of flu vaccine improves immune response in the elderly
7. NIAID media availability: New study describes key protein from highly pathogenic H5N1 avian flu virus and how it might mutate
8. NIAID media availability: Understanding influenza infection
9. NIAID researchers show how promising TB drug works
10. NIAID awards $47 million to develop medical countermeasures against radiological, nuclear threats
11. NIAID launches first Phase II trial of a global HIV/AIDS vaccine

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/31/2018)... ... ... Saturday, September 1st, 2018, Team Fastrax™ will perform their fan favorite patriotic ... At 7pm, the Cyclones will kick off against the South Dakota State Jackrabbits. Just ... jump in with their majestic 2,000 sq. ft. American Flag, red white and blue ...
(Date:8/31/2018)... ... August 31, 2018 , ... ... a small molecule drug discovery and development firm based in the Frederick ... to develop a first-in-class therapeutic targeting rare immune-mediated blood disorders, beginning with ...
(Date:8/29/2018)... ... August 29, 2018 , ... ... announced a new immunization module that allows independent pharmacies to start or ... all-time lows, service-oriented independent pharmacies are moving toward providing immunization programs in ...
(Date:8/29/2018)... ... August 29, 2018 , ... The Vape Mall has ... to provide information on the similarities and differences between smoking and vaping. , ... more importantly, differences between vaping and smoking. To accurately inform consumers on both ...
(Date:8/29/2018)... ... August 29, 2018 , ... National Senior Citizens Day ... when the facility was recognized for outstanding service by a proclamation from the ... August 21st ceremony by United Healthcare’s Angie Martinez, who nominated Pathways Memory Care ...
Breaking Medicine News(10 mins):
(Date:9/13/2018)... (PRWEB) , ... September 13, 2018 , ... ... is now available to test and ensure correct implementation of the NCPDP ... SCRIPT Version 2017071 includes important functionality and transactions identified by the industry as ...
(Date:9/12/2018)... (PRWEB) , ... September 12, 2018 , ... ... + Revenue Cycle Conference in Chicago, IL, from September 19-22. The IT + ... value of patient engagement and empowerment with the use of Precision Virtual Reality™ ...
(Date:9/7/2018)... ... September 06, 2018 , ... This year, the California Society of ... his presentation of: IDEAL IMPLANT® - Seven-Year Clinical Trial Results at the 68th CSPS ... at the upcoming ASPS (American Society of Plastic Surgeons) meeting in Chicago this fall. ...
Breaking Medicine Technology:
Cached News: